Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Monoclonal antibody therapies against anthrax Chen Z; Moayeri M; Purcell RToxins (Basel) 2011[Aug]; 3 (8): 1004-19Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: toxins and capsule. An extensive effort has been made to generate therapeutically useful monoclonal antibodies to each of the virulence components: protective antigen (PA), lethal factor (LF) and edema factor (EF), and the capsule of B. anthracis. This review summarizes the current status of anti-anthrax mAb development and argues for the potential therapeutic advantage of a cocktail of mAbs that recognize different epitopes or different virulence factors.|Animals[MESH]|Anthrax/immunology/*therapy[MESH]|Antibodies, Bacterial/blood/immunology[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Antigens, Bacterial/*immunology[MESH]|Antitoxins/immunology[MESH]|Bacillus anthracis/immunology/pathogenicity[MESH]|Bacterial Toxins/antagonists & inhibitors/*immunology[MESH]|Epitopes/immunology[MESH]|Humans[MESH]|Immunotherapy/*methods[MESH] |